Opportunity Information: Apply for PA 12 295
Apply for PA 12 295
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Drug Abuse Aspects of HIV/AIDS (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Sep 25, 2012 and posted on Sep 25, 2012.
- Applicants must submit their applications by Jan 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Public housing authorities/Indian housing authorities County governments Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Independent school districts Private institutions of higher education Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments For profit organizations other than small businesses Special district governments Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Drug Abuse Aspects of HIV/AIDS (R21) funding opportunity (PA 12-295) is a National Institute on Drug Abuse (NIDA) initiative under the National Institutes of Health (NIH) designed to support exploratory and developmental research that clarifies how drug abuse and addiction intersect with HIV/AIDS risk, transmission, progression, and outcomes. The FOA is specifically geared toward R21 projects, which are typically used to launch innovative, early-stage ideas, generate preliminary data, and test emerging hypotheses or intervention approaches that can later be scaled into larger studies. In practical terms, NIDA is looking for projects that help explain or reduce HIV risk and burden in populations affected by substance use, including both injection and non-injection drug users and their sexual partners.
The research scope spans several connected areas. One major emphasis is on drug-related risk behaviors that contribute to HIV transmission, such as injection practices, sharing of injection equipment, sexual risk behaviors that occur in the context of intoxication or addiction, and broader social or network factors linked to drug use that can accelerate HIV spread. Another focus is the relationship between addiction and HIV disease itself, including how substances may affect adherence to HIV care, engagement and retention in treatment, immune function, viral load dynamics, or the ability of people living with HIV to maintain consistent prevention practices. The FOA also highlights interest in co-morbidities and consequences that arise when HIV and substance use disorders occur together, which can include mental health conditions, hepatitis and other infectious diseases, chronic health complications, and social harms that can worsen both HIV outcomes and recovery trajectories.
A central goal is to strengthen the ability to identify and predict changes in HIV epidemiology among drug-using populations. That includes research that detects emerging patterns of transmission, shifts in risk environments, new substances or modes of use that change exposure risk, and evolving demographic or geographic trends. NIDA is also encouraging studies that move beyond description and into action by developing and testing interventions for both primary prevention (preventing new infections) and secondary prevention (reducing onward transmission and improving outcomes among people already living with HIV). Interventions of interest can include behaviorally oriented approaches, service delivery models, or drug treatment-based strategies that improve HIV testing uptake, counseling, linkage to care, and sustained access to effective HIV treatment. The announcement also invites basic and mechanistic research examining HIV infection and AIDS pathogenesis in the context of drug abuse and addiction, recognizing that substances can influence biological pathways relevant to susceptibility, disease progression, and treatment response.
From an administrative standpoint, this is a discretionary grant opportunity using the NIH Exploratory/Developmental Research Grant mechanism (R21) within the broader category of education and health research, aligned with CFDA 93.279 (Drug Abuse and Addiction Research Programs). The listed award ceiling is $200,000, and there is no cost-sharing or matching requirement. The opportunity was posted on September 25, 2012, with an original and final closing date of January 7, 2016, and it was archived on February 7, 2016.
Eligibility is broad and includes many types of domestic applicants such as state, county, city, township, and special district governments; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; small businesses; other for-profit organizations; and nonprofit organizations both with and without 501(c)(3) status (with the exception noted for certain categories). The FOA also makes clear that a wide range of mission-driven institutions and organizations are eligible, including faith-based and community-based organizations, historically Black colleges and universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and Native American tribal governments and tribal organizations (including those not federally recognized). Importantly, non-U.S. entities are eligible to apply, including foreign organizations and foreign institutions, and non-domestic components of U.S. organizations may participate; foreign components, as defined by NIH policy, are allowed.
The sponsoring agency is the National Institutes of Health, with NIDA as the issuing institute. Applicants seeking the full official announcement and instructions are directed to the NIH grants page for PA 12-295, and technical access issues are routed to the NIH Office of Extramural Research (OER) webmaster contacts provided in the listing.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled The Drug Abuse Aspects of HIV/AIDS (R21) and is identified as PA 12-295.
Which agency and institute are sponsoring this grant?
The sponsoring agency is the National Institutes of Health (NIH), and the issuing institute is the National Institute on Drug Abuse (NIDA).
What is the purpose of this FOA?
This FOA supports exploratory and developmental research that clarifies how drug abuse and addiction intersect with HIV/AIDS risk, transmission, progression, and outcomes.
What grant mechanism does this opportunity use?
It uses the NIH Exploratory/Developmental Research Grant mechanism (R21), which is commonly used to launch innovative early-stage ideas, generate preliminary data, and test emerging hypotheses or intervention approaches that can later be scaled into larger studies.
What types of projects is NIDA looking for under this R21?
NIDA is looking for projects that help explain or reduce HIV risk and burden in populations affected by substance use, including injection and non-injection drug users and their sexual partners.
What research areas are included in the scope of this FOA?
The scope spans several connected areas, including:
- Drug-related risk behaviors contributing to HIV transmission (for example, injection practices, sharing injection equipment, and sexual risk behaviors occurring in the context of intoxication or addiction).
- Broader social or network factors linked to drug use that can accelerate HIV spread.
- The relationship between addiction and HIV disease (including effects on adherence, engagement and retention in care, immune function, viral load dynamics, and consistent prevention practices among people living with HIV).
- Co-morbidities and consequences when HIV and substance use disorders occur together (including mental health conditions, hepatitis and other infectious diseases, chronic health complications, and social harms).
- Research to identify and predict changes in HIV epidemiology among drug-using populations.
- Development and testing of interventions for primary and secondary prevention.
- Basic and mechanistic research on HIV infection and AIDS pathogenesis in the context of drug abuse and addiction.
Does this FOA include both behavioral and biomedical research?
Yes. The announcement includes interest in behavioral risk and intervention research, service delivery models, drug treatment-based strategies, and also basic and mechanistic research examining HIV infection and AIDS pathogenesis in the context of drug abuse and addiction.
What kinds of HIV risk behaviors are emphasized?
The FOA emphasizes drug-related behaviors that contribute to HIV transmission, including injection practices, sharing injection equipment, and sexual risk behaviors occurring in the context of intoxication or addiction, along with related social and network factors.
How does the FOA address HIV outcomes among people living with HIV who use drugs?
It highlights research on how substances may affect adherence to HIV care, engagement and retention in treatment, immune function, viral load dynamics, and the ability to maintain consistent prevention practices.
Are co-occurring conditions and broader consequences part of the research scope?
Yes. The FOA specifically highlights co-morbidities and consequences that arise when HIV and substance use disorders occur together, such as mental health conditions, hepatitis and other infectious diseases, chronic health complications, and social harms that may worsen HIV outcomes and recovery trajectories.
Is there an emphasis on detecting emerging HIV transmission patterns?
Yes. A central goal is to strengthen the ability to identify and predict changes in HIV epidemiology among drug-using populations, including emerging transmission patterns, shifting risk environments, new substances or modes of use that change exposure risk, and evolving demographic or geographic trends.
Does the FOA support intervention development and testing?
Yes. NIDA encourages studies that move beyond description into action by developing and testing interventions for:
- Primary prevention (preventing new HIV infections)
- Secondary prevention (reducing onward transmission and improving outcomes among people already living with HIV)
What kinds of interventions are of interest?
Interventions of interest can include behaviorally oriented approaches, service delivery models, or drug treatment-based strategies that improve HIV testing uptake, counseling, linkage to care, and sustained access to effective HIV treatment.
What is the CFDA number associated with this opportunity?
The opportunity is aligned with CFDA 93.279 (Drug Abuse and Addiction Research Programs).
What is the maximum award amount listed for this FOA?
The listed award ceiling is $200,000.
Is cost-sharing or matching required?
No. The listing states there is no cost-sharing or matching requirement.
When was this opportunity posted?
It was posted on September 25, 2012.
What were the closing dates for applications?
The listing shows an original and final closing date of January 7, 2016.
Is this funding opportunity still open?
No. The opportunity was archived on February 7, 2016, and the final closing date is listed as January 7, 2016.
Who is eligible to apply?
Eligibility is broad and includes many types of applicants, including:
- State, county, city, township, and special district governments
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Independent school districts
- Small businesses
- Other for-profit organizations
- Nonprofit organizations with and without 501(c)(3) status (with an exception noted for certain categories)
Are faith-based and community-based organizations eligible?
Yes. The FOA explicitly includes faith-based and community-based organizations among eligible applicants.
Are minority-serving institutions and tribal entities eligible?
Yes. The eligibility language includes organizations such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and Native American tribal governments and tribal organizations, including those not federally recognized.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The FOA states that non-U.S. entities are eligible, including foreign organizations and foreign institutions.
Can a U.S. organization include non-domestic components in the project?
Yes. The FOA indicates that non-domestic components of U.S. organizations may participate, and that foreign components (as defined by NIH policy) are allowed.
Where can applicants find the official announcement and instructions?
Applicants are directed to the NIH grants page for PA 12-295 to access the full official announcement and instructions.
Who should be contacted for technical access issues related to the announcement?
Technical access issues are routed to the NIH Office of Extramural Research (OER) webmaster contacts provided in the listing.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Industrial Zone Development
Previous opportunity: Drug Abuse Aspects of HIV/AIDS (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 12 295
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 12 295) also looked into and applied for these:
| Funding Opportunity |
|---|
| Mechanism for Time Sensitive Drug Abuse Research (R21) Apply for PAR 12 297 Funding Number: PAR 12 297 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Cancer Center Support Grants (CCSGs) for NCI designated Cancer Centers (P30) Apply for PAR 12 298 Funding Number: PAR 12 298 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| FY 2013 American Schools and Hospitals Abroad (ASHA) Program Worldwide Apply for APS ASHA 13 000001 Funding Number: APS ASHA 13 000001 Agency: Agency for International Development Category: Education Health Funding Amount: $2,000,000 |
| NLM Grants for Scholarly Works in Biomedicine and Health (G13) Apply for PAR 13 014 Funding Number: PAR 13 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Prescription Drug Abuse (R01) Apply for PA 13 015 Funding Number: PA 13 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prescription Drug Abuse (R21) Apply for PA 13 016 Funding Number: PA 13 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Early Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21) Apply for RFA CA 13 001 Funding Number: RFA CA 13 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research (R33) Apply for RFA CA 13 002 Funding Number: RFA CA 13 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Stage Development of Innovative Technologies for Biospecimen Science (R21) Apply for RFA CA 13 003 Funding Number: RFA CA 13 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Technologies for Biospecimen Science (R33) Apply for RFA CA 13 004 Funding Number: RFA CA 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Limited Competition Palliative Care Research Co Operative (PCRC) (U24) Apply for RFA NR 13 004 Funding Number: RFA NR 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) Apply for PAR 13 036 Funding Number: PAR 13 036 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exceptional Unconventional Research Enabling Knowledge Acceleration (EUREKA) for Neuroscience and Disorders of the Nervous System (R01) Apply for RFA NS 13 007 Funding Number: RFA NS 13 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| AIDS and Cancer Specimen Resource (ACSR) (UM1) Apply for RFA CA 13 005 Funding Number: RFA CA 13 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R01) Apply for PAR 13 048 Funding Number: PAR 13 048 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R21) Apply for PAR 13 049 Funding Number: PAR 13 049 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pain in Aging (R01) Apply for PA 13 058 Funding Number: PA 13 058 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pain in Aging (R21) Apply for PA 13 059 Funding Number: PA 13 059 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pain in Aging (R03) Apply for PA 13 060 Funding Number: PA 13 060 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Administrative Supplements to NCI Funded Research Projects Funding to Advance Research on Cancers in Women (Admin Supp) Apply for PAR 13 067 Funding Number: PAR 13 067 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 12 295", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.